Literature DB >> 29202593

Ipragliflozin and sodium glucose transporter 2 inhibitors to reduce liver fat: will the prize we sought be won?

Kalliopi Pafili1, Efstratios Maltezos1, Nikolaos Papanas1.   

Abstract

Keywords:  Ipragliflozin; NAFLD; Sodium glucose co-transporter 2 inhibitors; type 2 diabetes

Year:  2017        PMID： 29202593     DOI： 10.1080/14656566.2017.1413346

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


× No keyword cloud information.
  3 in total

Review 1.  Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones.

Authors:  K Pafili; S A Paschou; E Armeni; S A Polyzos; D G Goulis; I Lambrinoudaki
Journal:  J Endocrinol Invest       Date:  2022-03-18       Impact factor: 5.467

2.  Periodontal disease could be a potential risk factor for non-alcoholic fatty liver disease: An 11-year retrospective follow-up study.

Authors:  Hye-Sun Shin; Min-Hee Hong; Ja-Young Moon; Seon-Ju Sim
Journal:  Clin Oral Investig       Date:  2022-05-13       Impact factor: 3.606

Review 3.  Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.

Authors:  Kalliopi Pafili; Michael Roden
Journal:  Mol Metab       Date:  2020-11-19       Impact factor: 7.422
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.